We are ProQR, a company on a mission to create new medicines for patients in need. We focus on a group of diseases called rare diseases, with a very high need for new medicines. Out of the approximately 7,000 rare diseases, less than 400 have a treatment, and we intend to change that. To treat these diseases we use RNA therapies, a technology that allows us to address inherited diseases that are caused by a genetic defect. Our focus is on diseases that are very severe or life threatening, and have limited treatment options. Amongst others we work on the development of new medicines for several forms of inherited blindness such as Leberâs congenital amaurosis, Usher syndrome type 2 and autosomal dominant retinitis pigmentosa. Source
No articles found.
Beyond Air Inc. is a clinical-stage medical device and biopharmaceutical company d...
Beyond Air Inc. is a clinical-stage medical dev...
Stericycle is a multinational business-to-business services company with a core pu...
Stericycle is a multinational business-to-busin...
Anixa is focused on harnessing the bodyâs immune system in the fight against can...
Anixa is focused on harnessing the bodyâs imm...
We are a late stage biopharmaceutical company focused on the development and comme...
We are a late stage biopharmaceutical company f...
Knowledge Begets Confidence. Founded by proven and trusted Pharmaceutical and Medi...
Knowledge Begets Confidence. Founded by proven ...
Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TSX: FRX) is a specialty pharmaceutic...
Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TS...
BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat...
BioCryst Pharmaceuticals discovers novel, oral ...
Join the National Investor Network and get the latest information with your interests in mind.